Serum serotonin concentration in lean and obese dogs with myxomatous mitral valve disease

  • Kim, Kyu-Tae (College of Veterinary Medicine, Chungnam National University) ;
  • Park, Hee-Myung (College of Veterinary Medicine, Konkuk University) ;
  • Hyun, Changbaig (College of Veterinary Medicine, Kangwon National University) ;
  • Seo, Kyoung-Won (College of Veterinary Medicine, Chungnam National University) ;
  • Song, Kun-Ho (College of Veterinary Medicine, Chungnam National University)
  • Received : 2016.03.21
  • Accepted : 2016.08.09
  • Published : 2016.12.31


The aim of the present study is to investigate the potential influence of obesity as a factor in 5-hydroxytryptamine (5-HT) concentration in myxomatous mitral valve disease (MMVD) dogs. Fifty-five client-owned dogs were enrolled in a randomized trial. Dogs were classified by echocardiography into healthy (control), mild, and moderate to severe MMVD groups. Each group was subclassified by using a 9-point body condition score (BCS); lean (BCS 5-6/9) and obese groups (BCS 7.5-9/9). Dogs with moderate to severe MMVD had lower serotonin (5-HT) concentrations than the control group (p = 0.03). Dogs with moderate to severe MMVD (p = 0.017) had lower serum 5-HT concentrations than the control group in the obese group (BCS 7.5-9/9). Significant difference was found between the lean and obese groups (p = 0.015) which are not consider severe in the MMVD group. These results suggested that 5-HT concentration was decreased with the increasing severity of MMVD, and obesity might be taken into consideration when interpreting the serotonin concentration in MMVD dogs.


Supported by : Chungnam National University


  1. Cornell CC, Kittleson MD, Della Torre P, Häggstrom J, Lombard CW, Pedersen HD, Vollmar A, Wey A. Allometric scaling of M-mode cardiac measurements in normal adult dogs. J Vet Intern Med 2004, 18, 311-321.
  2. Fitzgerald LW, Burn TC, Brown BS, Patterson JP, Corjay MH, Valentine PA, Sun JH, Link JR, Abbaszade I, Hollis JM, Largent BL, Hartig PR, Hollis GF, Meunier PC, Robichaud AJ, Robertson DW. Possible role of valvular serotonin 5-$HT_{2B}$ receptors in the cardiopathy associated with fenfluramine. Mol Pharmacol 2000, 57, 75-81.
  3. Fox PR. Pathology of myxomatous mitral valve disease in the dog. J Vet Cardiol 2012, 14, 103-126.
  4. Gustafsson BI, Tommeras K, Nordrum I, Loennechen JP, Brunsvik A, Solligard E, Fossmark R, Bakke I, Syversen U, Waldum H. Long-term serotonin administration induces heart valve disease in rats. Circulation 2005, 111, 1517-1522.
  5. Gustafsson BI, Hauso O, Drozdov I, Kidd M, Modlin IM. Carcinoid heart disease. Int J Cardiol 2008, 129, 318-324.
  6. Hora ek J, Kuzmiakova M, Hoschl C, And l M, Bahbonh R. The relationship between central serotonergic activity and insulin sensitivity in healthy volunteers. Psychoneuroendocrinology 1999, 24, 785-797.
  7. Laflamme D. Development and validation of a body condition score system for dogs. Canine Pract 1997, 22, 10-15.
  8. Ljungvall I, Hoglund K, Lilliehook I, Oyama MA, Tidholm A, Tvedten H, Haggstrom J. Serum serotonin concentration is associated with severity of myxomatous mitral valve disease in dogs. J Vet Intern Med 2013, 27, 1105-1112.
  9. Mangklabruks T, Surachetpong SD. Plasma and platelet serotonin concentrations in healthy dogs and dogs with myxomatous mitral valve disease. J Vet Cardiol 2014, 16, 155-162.
  10. Ni W, Watts SW. 5-Hydroxytryptamine in the cardiovascular system: focus on the serotonin transporter (SERT). Clin Exp Pharmacol Physiol 2006, 33, 575-583.
  11. Oyama MA, Chittur SV. Genomic expression patterns of mitral valve tissues from dogs with degenerative mitral valve disease. Am J Vet Res 2006, 67, 1307-1318.
  12. Park HJ, Lee SE, Oh JH, Seo KW, Song KH. Leptin, adiponectin and serotonin levels in lean and obese dogs. BMC Vet Res 2014, 10, 113.
  13. Pedersen HD, Haggstrom J. Mitral valve prolapse in the dog: a model of mitral valve prolapse in man. Cardiovasc Res 2000, 47, 234-243.
  14. Young SN. How to increase serotonin in the human brain without drugs. J Psychiatry Neurosci 2007, 32, 394-399.